Cargando…
A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro
PURPOSE: The primary goal of the present study was to develop the nano-drug consisting of doxorubicin and exosome derived from mesenchymal stem cells, and to explore its effect on osteosarcoma in vitro. METHODS: The exosomes were isolated from bone marrow MSCs (BM-MSCs) by an Exosome Isolation Kit....
Autores principales: | Wei, Hongxiang, Chen, Jinyuan, Wang, Shenglin, Fu, Feihuan, Zhu, Xia, Wu, Chaoyang, Liu, Zhoujie, Zhong, Guangxian, Lin, Jianhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830377/ https://www.ncbi.nlm.nih.gov/pubmed/31802872 http://dx.doi.org/10.2147/IJN.S218988 |
Ejemplares similares
-
Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis
por: Wei, Hongxiang, et al.
Publicado: (2022) -
The Clinical Significance of the Expression of FEN1 in Primary Osteosarcoma
por: Zhong, Guangxian, et al.
Publicado: (2021) -
Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy
por: Zhu, Jianshu, et al.
Publicado: (2023) -
Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo
por: Wang, Jinkui, et al.
Publicado: (2022) -
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
por: Zeng, Yunxin, et al.
Publicado: (2021)